Masimo's Danaher Merger Caps a Turnaround Quarter That No Longer Matters

Masimo Corporation (NASDAQ: MASI) reports first-quarter 2026 earnings on Monday, May 26, 2026, with analysts expecting $1.41 per share on revenue estimates that remain undisclosed. The central question: can the medical technology company sustain its impressive streak of double-digit earnings beats while navigating tariff headwinds and maintaining the strong growth trajectory that drove preliminary full-year 2025 revenue to $1.52 billion? With the stock trading near all-time highs and technical indicators flashing uniformly bullish signals, investors will scrutinize whether management's guidance justifies current valuations or signals caution ahead.

Part 1: Earnings Preview

Masimo Corporation is a global medical technology leader specializing in noninvasive patient monitoring solutions, including its flagship SET® pulse oximetry technology used on more than 200 million patients annually across all 10 top-ranked U.S. hospitals. The company's portfolio spans hospital automation platforms, connectivity solutions, and telehealth technologies that are reshaping care delivery both inside and beyond hospital walls.

For the first quarter of 2026, Wall Street expects Masimo to deliver $1.41 per share, representing +3.68% growth compared to the $1.36 reported in Q1 2025. The consensus reflects estimates from four analysts ranging from $1.35 to $1.49. Most recently, the company reported $1.32 per share for Q3 2025, marking the third consecutive quarter of substantial earnings beats.

Three key themes define this earnings story:

Tariff Impact and Margin Pressure: Management's January preliminary results explicitly flagged "the impact of new tariffs" on 2025 non-GAAP EPS, which came in at the high end of guidance at $5.55. With tariffs remaining a wildcard for 2026, investors will scrutinize whether Masimo can maintain pricing power and operational efficiency, or if margin compression will force guidance revisions. The company's ability to navigate these headwinds while sustaining double-digit revenue growth will be critical.

Momentum in Core Monitoring Business: Preliminary 2025 results showed approximately 270,000 noninvasive technology board and instrument shipments, with Q4 2025 revenue hitting $411 million—representing 12% reported growth and 11% constant-currency growth. The question is whether this momentum accelerated into Q1 2026 or if comparisons are becoming more challenging as the base grows larger.

Full-Year 2026 Guidance Clarity: With preliminary 2025 results announced in January but full-year 2026 guidance still pending, this earnings call represents management's first comprehensive outlook for the current fiscal year. Analysts will focus on whether the company can sustain high-single-digit to low-double-digit revenue growth while expanding margins, or if tariff pressures and competitive dynamics force a more conservative posture.

Analyst commentary ahead of the release remains cautious. The consensus rating sits at 3.00 (Hold) with all 10 covering analysts maintaining neutral stances—no buy or sell recommendations in the mix. The average price target of $176.40 implies minimal upside from current levels, suggesting the Street views the stock as fairly valued heading into the print. This unanimously neutral positioning indicates analysts are waiting for concrete 2026 guidance before adjusting their stances, making management's forward commentary potentially more impactful than the Q1 results themselves.

Part 2: Historical Earnings Performance

Masimo has established a remarkably consistent pattern of exceeding Wall Street expectations, delivering three consecutive double-digit earnings beats through the first three quarters of 2025. The company reported $1.36 in Q1 2025 against a $1.24 estimate (+9.68% beat), followed by $1.33 versus $1.23 in Q2 (+8.13% beat), and $1.32 against $1.19 in Q3 (+10.92% beat). This track record demonstrates management's ability to consistently outperform guidance, with beats averaging nearly 10% above consensus.

The magnitude of these surprises has remained stable across quarters, suggesting operational execution rather than sandbagging estimates. Each beat fell within a tight 8-11% range, indicating predictable outperformance rather than volatile swings. With the current Q1 2026 estimate of $1.41 representing only +3.68% growth versus the $1.36 reported a year ago, the bar appears set for another potential beat—though investors should note the year-over-year comparison reflects more modest growth expectations than the double-digit beats suggest.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Masimo typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results drop, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price action reveals significant volatility around Masimo earnings, with the stock averaging 9.91% absolute moves on Day +1 and intraday ranges averaging 11.08%. The most dramatic reactions occurred in recent quarters: Q2 2025 saw an 11.73% decline on Day +1 despite beating estimates, while Q4 2024 delivered a 12.35% surge. Q3 2024 produced a 10.60% gain, and Q2 2024 jumped 11.29%—demonstrating that double-digit swings in either direction are the norm rather than the exception.

Day 0 moves average a more modest 2.22%, with Day 0 ranges of 3.83%, suggesting limited anticipatory positioning before results. The real action consistently arrives on Day +1, when the full weight of earnings, guidance, and management commentary hits the tape. Investors should prepare for potential moves approaching or exceeding 10% in either direction, with recent history showing the stock can swing violently even on earnings beats—suggesting guidance and forward commentary often matter more than the headline numbers.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 0.86% for the upcoming earnings release, dramatically understating the historical reality. This implied move is less than one-tenth of the 9.91% average absolute Day +1 move observed over the past seven quarters, suggesting options are significantly underpricing potential volatility and may present opportunity for volatility buyers.

Part 3: What Analysts Are Saying

Analyst sentiment toward Masimo remains firmly neutral, with the consensus rating at 3.00 (Hold) based on 10 analysts—all of whom maintain hold ratings with zero buy or sell recommendations. This unanimous middle-ground positioning reflects a wait-and-see approach, with the Street apparently viewing the stock as fairly valued at current levels and awaiting clearer visibility on 2026 guidance before committing to directional calls.

The average price target sits at $176.40, implying just 1.4% downside from the current price of $178.81. The narrow target range spans from a low of $162.00 to a high of $180.00, suggesting limited conviction in either direction. Notably, sentiment has remained unchanged over the past month, indicating no recent catalyst has shifted the analyst community's neutral stance.

This consensus caution stands in stark contrast to the stock's strong technical momentum and consistent earnings beats. The lack of buy ratings despite three consecutive quarters of 8-11% earnings surprises suggests analysts may be concerned about valuation, tariff impacts, or the sustainability of recent growth rates. The upcoming earnings call—particularly management's full-year 2026 guidance—will be critical in determining whether this neutral wall cracks toward bullish upgrades or defensive downgrades.

Part 4: Technical Picture

Masimo enters earnings with exceptionally strong technical momentum, as the Barchart Technical Opinion registers 100% Buy currently, up from 88% Buy one week ago and matching the 100% Buy reading from one month ago. This strengthening signal reflects powerful near-term momentum as the stock trades at multi-year highs.

Timeframe Analysis:

• Short-term (100% Buy): Maximum bullish signal indicates powerful near-term momentum with buyers firmly in control heading into the earnings event
• Medium-term (100% Buy): Sustained strength across the intermediate timeframe confirms the uptrend is well-established beyond just short-term momentum
• Long-term (100% Buy): Maximum long-term bullish reading suggests the broader trend structure remains intact with no signs of deterioration

Trend Characteristics: The trend is characterized as Strong but Weakening, suggesting that while momentum remains powerfully bullish across all timeframes, some internal deterioration may be developing beneath the surface—a potential warning sign as the stock approaches earnings with elevated expectations.

The moving average structure confirms the bullish setup, with the stock trading above all key averages: the 5-day ($178.77), 10-day ($178.61), 20-day ($178.54), 50-day ($178.17), 100-day ($164.39), and 200-day ($154.25).

The clustering of short-term moving averages near the current price around $178-179 suggests the stock is consolidating at elevated levels, while the significant separation from longer-term averages—particularly the 100-day at $164.39 and 200-day at $154.25—illustrates the magnitude of the recent rally. This technical setup is supportive heading into earnings, with all moving averages in proper bullish alignment and no overhead resistance visible. However, the "Weakening" characterization despite maximum buy signals suggests momentum may be peaking, making the stock vulnerable to profit-taking if results or guidance disappoint. The tight clustering of near-term averages also means a sharp post-earnings decline could quickly trigger technical breakdowns, while a beat-and-raise scenario could propel the stock into uncharted territory with no technical resistance overhead.